Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.62
+0.13 (1.74%)
Nov 21, 2024, 4:00 PM EST - Market closed

Kezar Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2016
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2016
Revenue
-7----
Upgrade
Cost of Revenue
85.785.751.0138.94--
Upgrade
Gross Profit
-85.7-78.7-51.01-38.94--
Upgrade
Selling, General & Admin
23.6126.5420.1515.7211.979.98
Upgrade
Research & Development
-13.34---30.9827.36
Upgrade
Operating Expenses
10.2726.5420.1515.7242.9537.34
Upgrade
Operating Income
-95.96-105.24-71.16-54.66-42.95-37.34
Upgrade
Interest Expense
-1.6-1.55-1.19-0.16--
Upgrade
Interest & Investment Income
9.4611.14.110.191.212.26
Upgrade
EBT Excluding Unusual Items
-88.11-95.68-68.24-54.63-41.74-35.09
Upgrade
Merger & Restructuring Charges
-7.67-6.19----
Upgrade
Pretax Income
-95.78-101.87-68.24-54.63-41.74-35.09
Upgrade
Net Income
-95.78-101.87-68.24-54.63-41.74-35.09
Upgrade
Net Income to Common
-95.78-101.87-68.24-54.63-41.74-35.09
Upgrade
Shares Outstanding (Basic)
777542
Upgrade
Shares Outstanding (Diluted)
777542
Upgrade
Shares Change (YoY)
0.55%7.70%27.69%19.90%130.58%85.92%
Upgrade
EPS (Basic)
-13.15-14.04-10.13-10.35-9.49-18.39
Upgrade
EPS (Diluted)
-13.16-14.04-10.13-10.35-9.49-18.39
Upgrade
Free Cash Flow
-76.39-83.46-60.42-42.75-37.14-30.48
Upgrade
Free Cash Flow Per Share
-10.49-11.50-8.97-8.10-8.44-15.97
Upgrade
Operating Margin
--1503.39%----
Upgrade
Profit Margin
--1455.29%----
Upgrade
Free Cash Flow Margin
--1192.21%----
Upgrade
EBITDA
-94.9-104.17-70.14-53.15-41.41-36.04
Upgrade
D&A For EBITDA
1.061.071.021.511.541.3
Upgrade
EBIT
-95.96-105.24-71.16-54.66-42.95-37.34
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.